Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 4 Summary of rescue medication use-total grams used by visit (per-protocol set)

From: Comparison of two hyaluronic acid formulations for safety and efficacy (CHASE) study in knee osteoarthritis: a multicenter, randomized, double-blind, 26-week non-inferiority trial comparing Durolane to Artz

Time interval Statistic Artz Durolane
(5 × 2.5 ml) (1 × 3 ml, 4 × sham)
( n= 158) ( n= 161)
Pre treatment n (%) 2 (1.3%) 4 (2.5%)
  Mean (SD) 1.25 (0.35) 1.25 (0.87)
  Median 1.25 1.00
Week 4 to week 6 n (%) 20 (12.7%) 26 (16.1%)
  Mean (SD) 4.48 (5.81) 4.75 (5.41)
  Median 2.00 2.75
Week 6 to week 10 n (%) 13 (8.2%) 14 (8.7%)
  Mean (SD) 3.12 (3.90) 4.14 (6.13)
  Median 1.50 1.50
Week 10 to week 14 n (%) 10 (6.3%) 6 (3.7%)
  Mean (SD) 2.75 (3.83) 3.58 (3.76)
  Median 1.00 2.25
Week 14 to week 18 n (%) 9 (5.7%) 5 (3.1%)
  Mean (SD) 4.56 (6.05) 2.60 (2.30)
  Median 1.50 2.50
Week 18 to week 26 n (%) 21 (13.3%) 17 (10.6%)
  Mean (SD) 6.10 (6.28) 6.26 (6.94)
  Median 3.50 3.50
  1. Only patients that used rescue medication were included. Durolane from Q-med AB (Sweden) and Artz from Seikagaku Corporation (Japan). SD, standard deviation.